Superworth

Kardigan KARD

Drug Manufacturers - General, Healthcare
$12.80
+0.47%
Market cap
$1.2B
PE
n/m
one or more of the four quarters through 2026-06-30 missing
Forward PE
n/m
not a meaningful number
Price to sales
n/m
not a meaningful number
EV/EBIT
n/m
not a meaningful number
Revenue, 12 months
n/m
not a meaningful number
Net margin
n/m
not a meaningful number
Free cash flow yield
n/m
not a meaningful number

Charts

Financials

Income statement for KARD, by quarter
Income statementQ1 FY25Q2 FY25Q1 FY26Q2 FY26
R&D$18.8M$35.8M$45.1M$56.4M
SG&A$7.3M$21.3M$13.6M$18.9M
−$26.1M−$57.1M−$58.7M−$118.8M
Pre-tax income−$22.2M−$57.4M−$56.1M−$116.2M
−$4.2M$0$0$0
Net income−$18M−$57.4M−$56.1M−$116.2M
−$1.54−$4.64−$3.86−$4.61
11.7M12.4M14.5M25.2M

R&D: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.

SG&A: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.

Operating income: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.

Pre-tax income: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.

Income tax: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.

Net income: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.

EPS, diluted: Q1 FY25 and Q1 FY26: quarter's net income to common over its shares, to the cent.

Diluted shares: Q1 FY25 and Q1 FY26: share-days: the 6-month average less the second quarter's.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Drug Manufacturers - General nearest Kardigan's size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
KARDKardigan$1.2Bn/mn/an/mn/mn/m
OMEROmeros$1.2B10.9×11.7×n/mn/mn/m
AMPHAmphastar Pharmaceuticals$1.1B14.8×20.6×1.5×+1%10.8%
PCRXPacira BioSciences$1.5B104×65.6×1.9×+6%2.0%
ANABAnaptysbio$1.5B10.7×100.0×n/mn/mn/m
PAHCPhibro Animal Health$1.6B15.9×21.5×1.0×+17%6.6%
ANIPANI Pharmaceuticals$1.7B15.4×60.6×1.7×+31%11.1%
ABUSArbutus Biopharma$831M5.4×5.6×4.6×n/m84.2%
COLLCollegium Pharmaceutical$747.5M18.5×19.1×0.9×+14%5.9%
HRMYHarmony Biosciences$2.1B11.7×13.8×2.2×+24%18.9%
PBHPrestige Consumer Healthcare$2.3B13.4×15.3×2.0×−1%15.6%
Peer median$1.5B14.1×19.9×1.8×+14%10.9%

More on Kardigan

Each number over time

Its groups

About

Industry
Drug Manufacturers - General
Sector
Healthcare

Valuation data, not investment advice. Prices as of .